Professor, Internal Medicine, Virginia Commonwealth University, Medical College of Virginia School of Medicine
Internal Medicine
Dr. Bruce Hillner, MD
|
|
Give Review
Bruce Hillner, MD practices Internal Medicine. He attended University of Chicago Pritzker School of Medicine. University of Chicago Pritzker School of Medicine is ranked 10 in research and 19 in primary care medicine He has 10 awards "Fellow", "Professionalism in Practice Award (co-awardee w Thomas Smith)", "Distinguished Clinical Scientist of the Year", "Statesman Award (for lifetime service)", "Saenger Distinguished Service Award", "Senior Research Scholar in Health Policy & Outcomes Research", "Research Achievement Award", "Eminent University Scholar Professorship in Internal Medicine", "Faculty Research Award" and "Outstanding Paper by a Young Investigator". Dr. Bruce Hillner is also a published MD. He has 100 paper published. The most recent paper is: Review of cost-effectiveness assessments of chemotherapy in adjuvant and advanced breast cancer. Bruce Hillner, MD accepts Medicare payments and is listed with Medicare.gov.
Publications
- 18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry.
- Reply to C.G. Azzoli et al and C. Chouaid et al.
- Positron Emission Tomography for Subsequent Treatment Strategy in Oncology.
- Impact of 18F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry.
- Impact of 18F-Fluoride PET in Patients with Known Prostate Cancer: Initial Results from the National Oncologic PET Registry.
- Intended Versus Inferred Care After PET Performed for Initial Staging in the National Oncologic PET Registry.
- The Lack of Evidence for PET or PET/CT Surveillance of Patients with Treated Lymphoma, Colorectal Cancer, and Head and Neck Cancer: A Systematic Review.
- Intended Versus Inferred Management After PET For Cancer Restaging: Analysis of Medicare Claims Linked to a Coverage With Evidence Development Registry.
- Geographic and sociodemographic disparities in PET use by Medicare beneficiaries with cancer.
- Pharmacoeconomic issues in bisphosphonate treatment of metastatic bone disease.
- Is cancer care best at high-volume providers?
- Ensuring quality cancer care by the use of clinical practice guidelines and critical pathways.
- Burden of illness associated with metastatic melanoma: an audit of 100 consecutive referral center cases.
- Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma.
- Role of perspective and other uncertainties in cost-effectiveness assessments in advanced prostate cancer.
- The role of bisphosphonates in metastatic breast cancer.
- Predictors of Medicare costs in elderly beneficiaries with breast, colorectal, lung, or prostate cancer.
- Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care.
- Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
- American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.
- Current practice of temporary vena cava filter insertion: a multicenter registry.
- Cost-effectiveness of adding an electron-beam boost to tangential radiation therapy in patients with negative margins after conservative surgery for early-stage breast...
- Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women.
- Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis.
- Is the use of radiation therapy after mastectomy cost-effective?
- A sociodemographic and economic comparison of breast reconstruction, mastectomy, and conservative surgery.
- Role of decision analysis in relation to clinical trials and a US perspective of the Battelle model.
- Cost-effective use of autologous bone marrow transplantation: few answers, many questions, and suggestions for future assessments.
- Review of cost-effectiveness assessments of chemotherapy in adjuvant and advanced breast cancer.
- Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: report of a workshop.
- Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma.
- Hospital volume and patient outcomes in major cancer surgery: a catalyst for quality assessment and concentration of cancer services.
- A comparison of patterns of care of nonsmall cell lung carcinoma patients in a younger and Medigap commercially insured cohort.
- Does a clinical trial warrant an economic analysis?
- Overview of economic analysis of Le Chevalier Vinorelbine Study.
- Costs of care associated with non-small-cell lung cancer in a commercially insured cohort.
- Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer.
- Decision analysis: MIBI imaging of nonpalpable breast abnormalities.
- Economic analyses of benefit from interferon-alpha 2B in high-risk melanoma: trade-offs between completeness, simplicity and clarity.
- Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684.
- Measuring standards of care for early breast cancer in an insured population.
- High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.
- Decision analysis in non-small-cell lung cancer: not back to the drawing modeling board, back to the bedside.
- Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplant...
- Decision-theoretic refinement planning.
- Variation in staging and treatment of local and regional breast cancer in the elderly.
- Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Cl...
- Estimating the cost-effectiveness of stereotaxic biopsy for nonpalpable breast abnormalities: a decision analysis model.
- Genetic tests: a search for economy of scale.
- Economic considerations in the care of lung cancer patients.
- Differences in initial treatment patterns and outcomes of lung cancer in the elderly.
- Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
- Factors that determine the treatment for local and regional prostate cancer.
- Estimating the cost-effectiveness of flutamide in metastatic cancer.
- Economic and cost-effectiveness issues in breast cancer treatment.
- Pharmacoeconomics, quality of life, and combination modalities in non-small cell lung cancer: a panel discussion (Part 2).
- Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer.
- Decision analysis: a practical example.
- Cost effectiveness and other assessments of adjuvant therapies for early breast cancer.
- Trade-offs between survival and breast preservation for three initial treatments of ductal carcinoma-in-situ of the breast.
- Financial costs, benefits, and patient risk preferences in node-negative breast cancer: insights from a decision analysis model.
- Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes.
- The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women.
- Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis.
- Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model.
- Evaluating consensus among physicians in medical knowledge base construction.
- Ways to reduce the cost of oncology care without compromising the quality.
- Principles of cost effectiveness analysis for the assessment of current and new therapies.
- The costs and benefits of a screening program to detect dementia in older drivers.
- Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer.
- Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.
- Potential evaluation of the incremental cost-effectiveness of paclitaxel in advanced non-small-cell lung cancer (Eastern Cooperative Oncology Group 5592).
- Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials.
- Postmenopausal estrogens in prevention of osteoporosis. Benefit virtually without risk if cardiovascular effects are considered.
- Medical decision making: a Bayesian approach to laboratory testing.
- What a difference a day makes: a decision analysis of adult streptococcal pharyngitis.
- Basic principles of cost-effectiveness analysis.
- Physicians as gatekeepers. The impact of financial incentives.
- Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model.
- Optimal management of suspected lower-extremity deep vein thrombosis. An evaluation with cost assessment of 24 management strategies.
- A model of chemotherapy in node-negative breast cancer.
- Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial ...
- The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse.
- High-dose chemotherapy with autologous bone marrow transplantation for metastatic breast cancer.
- Estrogen therapy for geriatric osteoporosis: just one ball in a complex juggling act.
- Should women with node-negative breast cancer receive adjuvant chemotherapy?--Insights from a decision analysis model.
- Growth in the use of PET for six cancer types after coverage by medicare: additive or replacement?
- American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.
- Allocating cancer-directed expenditures: tensions between prevention, early detection and treatment is unnecessary.
- Explaining marginal benefits to patients, when "marginal" means additional but not necessarily small.
- Impact of dedicated brain PET on intended patient management in participants of the national oncologic PET Registry.
- ACP Journal Club. Use of paroxetine during tamoxifen therapy for breast cancer was associated with increased breast-cancer and all-cause mortality.
- Concrete options and ideas for increasing value in oncology care: the view from one trench.
- Comment on pegylated liposomal Doxorubicin plus docetaxel in metastatic breast cancer.
- PET and PET/CT reports: observations from the National Oncologic PET Registry.
- ACP Journal Club. Risk for breast cancer declined after postmenopausal hormone therapy was stopped.
- Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing.
- The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry.
- Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry.
Schools
University Of ChicagoThe Pritzker School Of Medicine
Michael Reese Med Center
University Cincinnati Med Center
Tufts University New Eng Med Center
Doctors Specialties
- Internal Medicine
Accepted Insurances
Awards
- Fellow
- Professionalism in Practice Award (co-awardee w Thomas Smith)
- Distinguished Clinical Scientist of the Year
- Statesman Award (for lifetime service)
- Saenger Distinguished Service Award
- Senior Research Scholar in Health Policy & Outcomes Research
- Research Achievement Award
- Eminent University Scholar Professorship in Internal Medicine
- Faculty Research Award
- Outstanding Paper by a Young Investigator
Education
-
Tufts Medical Center -
University Hospital - University of Cincinnati College of Medicine -
University of Chicago Pritzker School of Medicine
Drug Facts
| NPI NUMBER | 1295825834 | |
| NPPES Provider LastName | HILLNER | |
| NPPES Provider FirstName | BRUCE | |
| NPPES Provider ZIPCode | 232985051 | |
| NPPES Provider State | VA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 2465.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 160.0 | |
| Percent Opioid Claims | 6.49 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1295825834 |
| Last Name Of The Provider | HILLNER |
| First Name Of The Provider | BRUCE |
| View All |
Similar Doctors
|
|
Dr. Scott D. Harrison, MD |
|
|
Dr. Sindhura Bobba, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles H. Robertson Jr., MD |
|
|
Dr. Chathur Acharya, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Richard C. Peebles, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alice Wong, MD |
|
|
Dr. Mark Williams, MD |
|
|
Dr. Amit Bharara, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Peter Mills |